Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu
NCT05303493
 Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Melanoma
Non Small Cells - Lung |
Dr. Nathalie Daaboul
Marilyn Tessier
450-466-5000 poste 7691
|
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu
NCT05303493
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Melanoma
Non Small Cells - Lung |
Dr. Bertrand Routy
Wiam Belkaid
514-890-8000
|
A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial
STABLE-MATES Trial (JoLT-Ca)
NCT02468024
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Édith Filion
Dr. Moishe Liberman
Adeline Jouquan
514-890-8000 poste 26214
|
Study of the function and phenotype of tumor infiltrating lymphocytes in non-small cell lung cancer (Main study)
QC-CAPRION
n.d.
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Moishe Liberman
Adeline Jouquan
514-890-8000 poste 26214
|
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
M18-868
NCT04928846
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Non Small Cells - Lung |
Dr. Nathalie Daaboul
Marie-Ève Yelle
450-466-5000 poste 3281
|
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Krascendo 170
NCT05789082
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Non Small Cells - Lung |
Dr. Jennifer Friedmann
Chadi Zakaria
514-340-8222 poste 28326
|
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ?50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
TROPION-Lung08
NCT05215340
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
HOPITAL SANTA CABRINI OSPEDALE
|
Non Small Cells - Lung |
Dr. Michael Palumbo
Sabrina Sanzari
514-252-6000 poste 6677
|
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
eVOLVE-Lung02
NCT05984277
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Non Small Cells - Lung |
Dr. Marie-Ève Boucher
Pierre Bédard
418-835-7121
|
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ?50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
TROPION-Lung08
NCT05215340
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Benjamin Shieh
Nicola Raby
514-934-1934 poste 34095
|
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
TRUST-II
NCT04919811
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Non Small Cells - Lung |
Dr. Scott Owen
Nicola Raby
514-934-1934 poste 34095
|
Groupe d'étude en oncologie du Québec